UNITED STATES                        ----------------------------------
     WASHINGTON, D.C. 20549
                                              OMB Number:
          FORM 12b-25                         Expires:
                                              Estimated average burden
                                              hours per response

                                                    CUSIP NUMBER


(Check One):  [x] Form 10-K  [ ] Form 20-F  [ ] Form 11-K
              [ ] Form 10-Q  [ ] Form N-SAR

                     For the Period Ended: January 31, 2003

[  ] Transition Report on Form 10-K
[  ] Transition Report on Form 20-F
[  ] Transition Report on Form 11-K
[  ] Transition Report on Form 10-Q
[  ] Transition Report on Form N-SAR

                For the Transition Period Ended:_________________

          Read Instruction Before Preparing Form. Please Print or Type.

         Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.

         If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:


                         PART I - REGISTRANT INFORMATION

Full Name of Registrant:  BioSpecifics Technologies Corp.

Former Name if Applicable:  N/A

Address of Principal Executive Office (Street and number):  35 Wilbur Street

City, State and Zip Code:  Lynbrook, New York  11563

                        PART II - RULES 12b-25(b) AND (c)

         If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)

     | (a)     The reasons described in reasonable detail in Part III of this
     |         form could not be eliminated without unreasonable effort or
     |         expense;
     | (b)     The subject annual report, semi-annual report, transition report
     |         on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof,
     |         will be filed on or before the fifteenth calendar day following
[X}  |         the prescribed due date; or the subject quarterly report of
     |         transition report on Form 10-Q, or portion thereof will be filed
     |         on or before the fifth calendar day following the prescribed due
     |         date; and
     | (c)     The accountant's statement or other exhibit required by Rule
     |         12b-25(c) has been attached if applicable.

                              PART III - NARRATIVE

         State below in reasonable detail the reasons why Forms 10-K, 20-F,
11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be
filed within the prescribed time period. (Attach extra sheets if needed.)

         The Company's Annual Report on Form 10-KSB will not be filed within the
prescribed time period because of unexpected delays in the preparation of
the 10-KSB.

                           PART IV - OTHER INFORMATION

         Name and telephone number of person to contact in regard to this

          Albert Horcher             516                     593-7000
          --------------         -----------              -----------------
            (Name)               (Area Code)             (Telephone Number)

(1)      Have all other periodic reports required under Section 13 or 15(d) of
         the Securities Exchange Act of 1934 or Section 30 of the Investment
         Company Act of 1940 during the preceding 12 months or for such shorter
         period that the registrant was required to file such report(s) been
         filed? If answer is no, identify report(s).
                                                           [X] Yes      [ ] No

(2)      Is it anticipated that any significant change in results of operations
         from the corresponding period for the last fiscal year will be
         reflected by the earnings statements to be included in the subject
         report or portion thereof?
                                                           [X] Yes       [ ] No

         If so, attach an explanation of the anticipated change, both
         narratively and quantitatively, and, if appropriate, state the reasons
         why a reasonable estimate of the results cannot be made.

         For the year ended January 31, 2002, the Company's net loss was
         approximately ($257,000). For the year ended January 31, 2003, the
         Company anticipates a net loss of approximately ($3,000,000).

         Net sales recorded during the fiscal years ended January 31, 2003 and
         2002 were primarily from deliveries of stockpiled enzyme inventory to
         the Company's US customer. We depleted the stockpiled enzyme inventory
         available for use by that customer during the second quarter of the
         fiscal year ended January 31, 2003, and as a result, net sales were
         negatively impacted during the remainder of the year, and insufficient
         to cover expenses.


                         BioSpecifics Technologies Corp.
                  (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

Date:  May 1, 2003                 By:  /s/ Albert Horcher
       -----------------                -----------------------------------
                                        Name: Albert Horcher
                                        Title:  Secretary, Treasurer, Principal
                                        Financial and Chief Accounting Officer